Researchers discover new ‘rules of engagement’ that allow viruses such as HIV to infect healthy cells

10 June 2015

An international team of researchers, led by scientists from the Francis Crick Institute and Imperial College London, has discovered important new detail on how retroviruses take over healthy cells. 

The research, published today in Nature, may eventually lead to more effective treatments to suppress the virus in people who have been infected. 

Retroviruses, such as HIV, insert their genomes into the chromosomes of host cells, an irreversible process which makes them particularly difficult to eradicate. The viral enzyme responsible for this process is called integrase and it is carried by every retrovirus. Using a very powerful electron microscope, the research team discovered how integrase captures tightly wound packages of human DNA called nucleosomes, in order to insert the viral DNA.   

Cryo-electron microscopy structure of a retroviral integrase attacking a human nucleosome.

Cryo-electron microscopy structure of a retroviral integrase attacking a human nucleosome. This macromolecular assembly represents a key intermediate during the integration of the retrotrascribed viral genome into host-cell chromosomes.

 

Principal Investigator Peter Cherepanov, from the Francis Crick Institute and Imperial College London, said: "Cellular DNA is tightly packaged in the form of nucleosomal arrays, with each nucleosome acting as a tiny reel. This compaction could be expected to present an obstacle for viral integration. In the course of this study, we were able to explain how the virus captures and opens -up human nucleosomes to insert its DNA into a human chromosome. 

"The more we learn about the rules of engagement between the viral integration machinery and host cells, the easier it will become for us to break the chain of events that lead to persistent infection. This can lead to more effective antiretroviral drugs to treat HIV infection.

"There is also a potential benefit for gene therapy. The unique ability of retroviruses to efficiently integrate their genetic material into host cell chromosomal DNA means they could be used to deliver highly targeted drugs as part of gene therapy. However, uncontrolled integration by retroviruses carries the risk of serious side effects. Understanding how to selectively direct integration will potentially aid the development of safer gene therapy."

Another Francis Crick Institute lead investigator on the study, Alessandro Costa, explained how the integrase-nucleosome complex was visualised: "Starting from 2D images of individual molecular assemblies, we have reconstructed a high-resolution 3D view of integrase attacking a tiny fragment of a human chromosome, 10 billionths of a metre in diameter. This achievement, unconceivable only four years ago, was made possible by using a very sophisticated electron microscope, new generation cameras and innovative software for data analysis.

"Biological nanomachines such as integrase can now be imaged in unprecedented detail as they perform their work. Thanks to these new tools we can rethink the way we ask scientific questions".

Sir Paul Nurse, director of the Francis Crick Institute, said: "This is a fascinating and important discovery which increases our understanding of the way retroviruses work. It has important long-term implications, not only for leading to improvements in HIV treatments but also for treating a range of other diseases which may benefit from gene therapy." 

The research team included scientists from Imperial College London, the Dana-Farber Cancer Institute in Boston, the Gorlaeus Laboratory in Leiden, and the Institute of Virology in Dresden. 

The work was supported by funding from the European Commission and National Institutes of Health. 

 

Notes to Editors: 

The Francis Crick Institute is a new and distinctive medical research institute. Its purpose built laboratory in the King's Cross area of London will open at the end of 2015.  The institute's work - which is already underway at the Crick's Clare Hall, Lincoln's Inn Fields and Mill Hill laboratories - will help to understand why disease develops. We will find new ways to diagnose, prevent and treat a range of illnesses − such as cancer, heart disease and stroke, infections and neurodegenerative diseases. We will bring together outstanding scientists from all disciplines, carrying out research that will help improve the health and quality of people's lives, and keeping the UK at the forefront of medical innovation. 

The Francis Crick Institute is a charity supported by the Medical Research Council, Cancer Research UK, the Wellcome Trust, UCL (University College London), Imperial College London and King's College London.